Alliancebernstein L.P. Sells 151,479 Shares of MEDNAX, Inc. (NYSE:MD)

Alliancebernstein L.P. decreased its position in MEDNAX, Inc. (NYSE:MD) by 2.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,577,437 shares of the company’s stock after selling 151,479 shares during the quarter. Alliancebernstein L.P. owned approximately 0.08% of MEDNAX worth $186,997,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MD. State Street Corp increased its holdings in shares of MEDNAX by 2.5% during the second quarter. State Street Corp now owns 3,175,996 shares of the company’s stock valued at $95,756,000 after acquiring an additional 76,449 shares in the last quarter. Principal Financial Group Inc. increased its holdings in shares of MEDNAX by 3.7% during the second quarter. Principal Financial Group Inc. now owns 726,311 shares of the company’s stock valued at $21,898,000 after acquiring an additional 25,851 shares in the last quarter. Bridgewater Associates LP bought a new position in shares of MEDNAX during the second quarter valued at $2,488,000. Renaissance Technologies LLC bought a new position in shares of MEDNAX during the second quarter valued at $9,386,000. Finally, Eqis Capital Management Inc. bought a new position in shares of MEDNAX during the second quarter valued at $201,000. Institutional investors and hedge funds own 96.76% of the company’s stock.

In other MEDNAX news, Director Roger Md Medel sold 59,893 shares of the firm’s stock in a transaction dated Monday, January 10th. The stock was sold at an average price of $26.44, for a total value of $1,583,570.92. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider John C. Pepia sold 9,238 shares of the firm’s stock in a transaction dated Friday, October 29th. The stock was sold at an average price of $26.87, for a total value of $248,225.06. The disclosure for this sale can be found here. Insiders sold 267,547 shares of company stock worth $7,277,879 over the last three months. Insiders own 2.80% of the company’s stock.

NYSE MD opened at $26.91 on Friday. MEDNAX, Inc. has a one year low of $20.27 and a one year high of $35.67. The stock has a 50-day moving average of $26.60 and a 200 day moving average of $28.57. The company has a market capitalization of $2.33 billion, a price-to-earnings ratio of 122.32, a PEG ratio of 1.49 and a beta of 2.11. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.98 and a current ratio of 1.98.

MEDNAX (NYSE:MD) last announced its earnings results on Thursday, October 28th. The company reported $0.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.05. The business had revenue of $493.00 million for the quarter, compared to analysts’ expectations of $480.04 million. MEDNAX had a return on equity of 12.99% and a net margin of 1.05%. The business’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same period last year, the firm posted $0.33 earnings per share. On average, equities analysts predict that MEDNAX, Inc. will post 1.38 earnings per share for the current fiscal year.

Several equities analysts have recently weighed in on the company. Credit Suisse Group reduced their price target on MEDNAX from $33.00 to $32.00 and set an “outperform” rating for the company in a report on Wednesday, December 22nd. BMO Capital Markets reduced their price target on MEDNAX from $37.00 to $31.00 and set a “market perform” rating for the company in a report on Monday, November 1st. They noted that the move was a valuation call. Truist Securities reduced their price target on MEDNAX from $37.00 to $31.00 and set a “hold” rating for the company in a report on Wednesday, October 13th. SVB Leerink reduced their price objective on MEDNAX from $29.00 to $27.00 and set a “market perform” rating for the company in a report on Thursday, November 4th. Finally, Truist reduced their price objective on MEDNAX from $37.00 to $31.00 and set a “hold” rating for the company in a report on Wednesday, October 13th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $29.70.

About MEDNAX

MEDNAX, Inc provides physician services including newborn, anesthesia, maternal-fetal, tele radiology, pediatric cardiology and other pediatric subspecialty care. The firm’s solution include anesthesiology & pain management, prenatal, neonatal, pediatric, radiology, tele radiology, revenue cycle management and perioperative improvement consulting.

Featured Story: Systematic Risk

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX, Inc. (NYSE:MD).

Institutional Ownership by Quarter for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.